

Simris Biologics awarded €163,000 for the genetic engineering of cyanobacterial strains during an 18-month project beginning January 2024

Simris Group AB (publ) ("Simris Group" or the "Company") today confirms that its wholly owned subsidiary Simris Biologics GmbH based in Berlin, Germany, has had its tender approved by Helmholtz-Zentrum Berlin für Materialien und Energie GmbH (HZB) as part of its project, "Enhanced cyanobacterial protein colourants for food industry, solar technology and scientific applications – PHYCOLOR". HZB has awarded Simris Biologics €163,732 for its contribution to their project.

The role of Simris Biologics in the project will be to provide full-service R&D for the genetic engineering of cyanobacterial strains aimed at optimising the production and stability of phycocyanin, a powerful antioxidant with many health benefit claims including boosting the immune system, inhibiting the growth of certain cancers and brain health. Owing to its intense blue colour, phycocyanin can be used as a natural food colourant, or as a natural dye for textiles, however the colour is not always stable. The goal of this research project is to producing a more colour-stable phycocyanin, thereby increasing its attractiveness as a colourant or dye in the food and textile industry respectively.

Simris Group CEO, Julian Read commented "I am delighted that HZB has awarded us this tender to support their project. It recognises our capability as a global expert in the genetic engineering of cyanobacteria, and highlights the value of our library of 1,200 cyanobacterial producer strains. The team in Berlin are ideally placed to optimise cyanobacteria strains to produce a more stable phycocyanin. Furthermore, through our involvement, Simris will be well placed to support the commercialisation of the developed technology."

Contact Details:

Julian Read
CEO Simris Group AB
Email: ir@simris.com
Mobile: +46767888212
www.simrisgroup.com

About Simris Group AB (PUBL):

Simris Group is a biologics company identifying high value, natural, biologically active compounds found in microalgae and cyanobacteria to extract for applications in skincare, nutrition, and biopharmaceuticals. The company sustainably grows microalgae and cyanobacteria at industrial scale within its photobioreactor facility whereby conditions are optimized for production of these high-value compounds.

Simris Group's shares are traded on the Nasdaq First North Growth Market with the short name SIMRIS and ISIN code SE0008091664.

Certified Adviser is Amudova AB, telephone: 08-546 017 58, email: info@amudova.se.

Attachments

[Simris Biologics awarded €163,000 for the genetic engineering of cyanobacterial strains during an 18-month project beginning January 2024](#)